The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FOENIX-CCA4: A phase 2 study of futibatinib 20 mg and 16 mg in patients with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor 2 (FGFR2) fusions/rearrangements.
 
Teresa Macarulla
Consulting or Advisory Role - Ability Pharma; Advance Medical; Amgen; Aptitude Health; AstraZeneca; Basilea; Baxter; BioLineRX; Celgene; Eisai; Ellipses Pharma; Esteve; Incyte; Ipsen; Janssen; Lilly; Medscape; MFAR, Marketing Farmacéutico & Investigación Clínica; MSD; Novocure; Paraxel; Prime Oncology; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Zymeworks
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Agios (Inst); Amc Medical Research (Inst); Amgen (Inst); Armo Biosciences (Inst); ASLAN Pharmaceuticals (Inst); ASTRAZENECA (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); Beigene (Inst); BiolineRx (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (BMS) (Inst); Cantargia AB (Inst); Celgene (Inst); Eisai (Inst); ERYTECH Pharma (Inst); Fibrogen (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Incyte (Inst); Ipsen (Inst); Keralty Group (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Millennium (Inst); Nelum Corp. (Inst); Novartis (Inst); Novocure (Inst); OncoMed (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Roche (Inst); VCN Biosciences (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Incyte; Merck; Prime Oncology; Sanofi; SERVIER
 
Takashi Mizuno
No Relationships to Disclose
 
Giovanni Brandi
Consulting or Advisory Role - Taiho Oncology
Research Funding - Incyte; Merck; MSD; Taiho Pharmaceutical
 
Jin Li
No Relationships to Disclose
 
Ming-Huang Chen
No Relationships to Disclose
 
Jung Hun Kang
No Relationships to Disclose
 
Kathia Cristina Abdalla
No Relationships to Disclose
 
Piotr Jan Wysocki
Honoraria - Immunicom Inc
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb/Medarex; Immunicom; Janssen; MSD Oncology; Pierre Fabre; Roche
Expert Testimony - Immunicom; Immunicom
Travel, Accommodations, Expenses - Gilead Sciences; Immunicom; Pierre Fabre
 
Nuno Couto
Consulting or Advisory Role - AstraZeneca; Roche
Speakers' Bureau - Novartis; SERVIER
Research Funding - Acceleron Pharma; Amgen; Gilead Sciences; Ipsen; Seagan; Taiho Pharmaceutical
Travel, Accommodations, Expenses - SERVIER
 
Bailey Anderson
Employment - Taiho Oncology
 
Hamdy Elsayed
Employment - Taiho Oncology
 
Parvez Mantry
No Relationships to Disclose